Lunde Hanne Marie Bøe, Assmus Jörg, Myhr Kjell-Morten, Bø Lars, Grytten Nina
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway.
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625. doi: 10.1136/jnnp-2016-315238. Epub 2017 Apr 1.
Survival and causes of death (COD) in multiple sclerosis (MS) provide ultimate endpoints. We aimed to investigate survival and COD in a 60-year population-based MS cohort compared with the general population.
All patients with incident multiple sclerosis (MS) (N=1388) with onset during 1953-2012 in Hordaland County, Western Norway, were included. Data were obtained from patient records at Haukeland University Hospital and linked to the Norwegian COD registry. Survival adjusted for sex, age and disease course were estimated by Kaplan-Meier analyses from birth and from disease onset. Mortality and COD in MS relative to the general population were examined by standardised mortality ratio (SMR).
Of 1388 patients, 291 had deceased, mainly of MS (56.4%). Median life expectancy was 74.7 years for MS and 81.8 years for the general population (p<0.001); 77.2 years for women with MS and 72.2 years for men with MS (p<0.001). Life expectancy for patients with relapsing remitting MS (RRMS) was 77.8 years and -71.4 years for primary progressive MS (PPMS) (p<0.001). Overall SMR was 2.7 (p>0.0001); 2.9 in women and 2.5 in men (p=0.0009). SMR was 2.4 in RRMS and 3.9 in PPMS (p<0.0001). SMR from disease onset during 1953-1974 was 3.1; 2.6 during 1975-1996 and 0.7 during 1997-2012 (p<0.0083). No difference in cause-specific deaths were found (p=0.0871).
We found a 7-year shorter life expectancy and almost threefold higher mortality in MS compared with the general population. A rise in survival in MS was observed during the entire observation period.
多发性硬化症(MS)的生存率和死亡原因提供了最终结局指标。我们旨在调查一个基于人群的60年MS队列与普通人群相比的生存率和死亡原因。
纳入1953年至2012年期间在挪威西部霍达兰郡发病的所有新发多发性硬化症(MS)患者(N = 1388)。数据来自豪克兰大学医院的患者记录,并与挪威死亡原因登记处相链接。通过Kaplan-Meier分析从出生和疾病发作时开始估计根据性别、年龄和病程调整后的生存率。通过标准化死亡率(SMR)检查MS相对于普通人群的死亡率和死亡原因。
在1388名患者中,291人已死亡,主要死于MS(56.4%)。MS患者的中位预期寿命为74.7岁,普通人群为81.8岁(p < 0.001);MS女性患者为77.2岁,男性患者为72.2岁(p < 0.001)。复发缓解型MS(RRMS)患者的预期寿命为77.8岁,原发性进展型MS(PPMS)患者为71.4岁(p < 0.001)。总体SMR为2.7(p > 0.0001);女性为2.9,男性为2.5(p = 0.0009)。RRMS的SMR为2.4,PPMS为3.9(p < 0.)。1953年至1974年疾病发作时的SMR为3.1;1975年至1996年为2.6,1997年至2012年为0.7(p < 0.0083)。未发现特定原因死亡存在差异(p = 0.0871)。
我们发现与普通人群相比,MS患者的预期寿命短7年,死亡率几乎高出三倍。在整个观察期内观察到MS患者生存率有所提高。